Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;29(5):559-563.
doi: 10.1097/LVT.0000000000000087. Epub 2023 Feb 8.

Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma

Lorenza Di Marco  1   2 , Alessandra Pivetti  1 , Francesco Giuseppe Foschi  3 , Roberto D'Amico  4 , Filippo Schepis  1 , Cristian Caporali  5 , Federico Casari  5 , Simone Lasagni  1   2 , Rosina Maria Critelli  1 , Fabiola Milosa  1 , Adriana Romanzi  1   2 , Gemma Marcelli  1 , Nicola De Maria  1 , Dante Romagnoli  1 , Barbara Catellani  6 , Filippo Scianò  1 , Paolo Magistri  6 , Antonio Colecchia  1 , Pamela Sighinolfi  7 , Fabrizio Di Benedetto  6 , Maria-Luz Martinez-Chantar  8 , Erica Villa  1
Affiliations

Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma

Lorenza Di Marco et al. Liver Transpl. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts to report.

Figures

FIGURE 1
FIGURE 1
(A) Liver biopsy performed 10 days after the first nivolumab infusion. HE staining shows prominent portal mixed inflammation with interface activity ([A], ×10, [B] ×20) and eosinophil infiltrate (B, white arrows). There is a presence of cytoplasmatic vacuolization of the duct epithelium consistent with bile duct damage ([B], red arrow). In [C (×10)] and [D (×20)], a representative example of subendothelial lymphocytic inflammation with lifting up of the endothelium compatible with endothelitis is shown (black arrows). (B), Kaplan–Meier curve for the survival of patients with recurrence of HCC after liver transplant after starting second-line therapy with Nivolumab/Bevacizumab (blue line), or Regorafenib (red line). Differences in survival were compared by the log-rank test. The orange line indicates the patient, who received only 1 Nivolumab infusion but died of rapid tumoral progression.
See this image and copyright information in PMC

References

    1. Invernizzi F, Iavarone M, Zavaglia C, Mazza S, Maggi U, Cesarini L, et al. Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation. Transplantation. 2020;104:568–574. - PubMed
    1. Iavarone M, Invernizzi F, Ivanics T, Mazza S, Zavaglia C, Sanduzzi-Zamparelli M, et al. Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation: a retrospective study. Liver Transpl. 2021;27:1767–1778. - PubMed
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. - PubMed
    1. Villa E, Critelli R, Lei B, Marzocchi G, Cammà C, Giannelli G, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. 2016;65:861–869. - PubMed
    1. Fodor D, Jung I, Turdean S, Satala C, Gurzu S. Angiogenesis of hepatocellular carcinoma: an immunohistochemistry study. World J Hepatol. 2019;11:294–304. - PMC - PubMed

Publication types

MeSH terms